Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • A switch regimen consisting of raltegravir—every 12 hours for 4 weeks and then every 24 hours for 4 weeks, or vice versa—in combination with atazanavir maintained undetectable HIV-1 RNA with stable CD4+ cell counts in all study subjects[Carey 2012]
    • Both regimens were generally well tolerated with no serious adverse events
  • Safety of a regimen consisting of unboosted atazanavir 200 mg twice daily and raltegravir 400 mg twice daily without NRTIs has been called into question because of an increased incidence of grade 3/4 hyperbilirubinemia[Kozal 2012]

Action required